<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684775</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-19497-2</org_study_id>
    <secondary_id>R01DA019497-02</secondary_id>
    <secondary_id>NA_00000928</secondary_id>
    <nct_id>NCT00684775</nct_id>
  </id_info>
  <brief_title>Employment-Based Depot Naltrexone Clinical Trial II</brief_title>
  <official_title>Employment-Based Depot Naltrexone Clinical Trial II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether employment-based naltrexone treatment
      proves effective in promoting depot naltrexone adherence and drug abstinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized study is planned to evaluate the effectiveness of employment-based reinforcement
      in promoting depot naltrexone adherence in opiate-dependent adults. Vivitrol, an
      extended-release depot formulation of naltrexone approved by the FDA for the treatment of
      alcohol dependence, will be used. Participants will be offered an inpatient opioid
      detoxification and oral naltrexone induction. Participants who complete the oral naltrexone
      induction (N=40) will be randomly assigned to one of two groups. Both groups will be invited
      to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months.
      Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition will earn access to working
      and earning salary by taking depot naltrexone injections once per month. &quot;Work Plus
      Naltrexone Prescription&quot; participants will be encouraged to take depot naltrexone monthly,
      but access to working and earning salary will not be contingent on doing so.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2008</start_date>
  <completion_date type="Actual">April 30, 2010</completion_date>
  <primary_completion_date type="Actual">April 30, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Naltrexone Injections Received</measure>
    <time_frame>24 weeks</time_frame>
    <description>The percentage of depot naltrexone doses that participants received</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the First Missed Dose</measure>
    <time_frame>24 weeks</time_frame>
    <description>The time to the first missed dose of depot naltrexone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of 30-day Urine Samples Negative for Opiates</measure>
    <time_frame>Collected every 30 days for 150 days</time_frame>
    <description>Percentage of urine samples collected at the 30-day assessments that are negative for opiates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of M-W-F Samples Negative for Cocaine</measure>
    <time_frame>Collected every Monday, Wednesday and Friday for 24 weeks</time_frame>
    <description>Percentage of urine samples collected Monday, Wednesday and Friday at the workplace that are negative for cocaine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Percentage of 30-day Urine Samples Negative for Cocaine</measure>
    <time_frame>Collected every 30 days for 150 days</time_frame>
    <description>The percentage of urine samples collected at 30-day assessments that are negative for cocaine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Risk Behaviors</measure>
    <time_frame>24 weeks</time_frame>
    <description>behaviors that place participants at risk for acquiring or transmitting HIV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of M,W,F Urine Samples Negative for Opiates</measure>
    <time_frame>Collected every Monday, Wednesday and Friday for 24 weeks</time_frame>
    <description>Percentage of urine samples collected Monday, Wednesday and Friday at the workplace that are negative for opiates</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>Work Plus Naltrexone Prescription</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants could work and earn vouchers but did not to take Vivitrol Injections to work and earn vouchers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Work Plus Naltrexone Contingency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants could work and earn vouchers and had to take Vivitrol Injections to work and earn vouchers: employment-based reinforcement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Work Plus Naltrexone Contingency</intervention_name>
    <description>Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition earned access to working and earning salary by taking depot naltrexone injections once per month.</description>
    <arm_group_label>Work Plus Naltrexone Contingency</arm_group_label>
    <other_name>contingency management</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Individuals were eligible if they:

          -  met the Diagnostic and Statistical Manual (DSM)-IV criteria for opioid dependence,

          -  reported using heroin at least 21 of the last 30 days while living in the community,

          -  were unemployed,

          -  were 18-65 years old,

          -  were medically approved for naltrexone,

          -  lived in or near Baltimore, MD.

        Individuals were excluded if they:

          -  were pregnant or breastfeeding,

          -  had serum aminotransferase levels over three times normal,

          -  had current hallucinations, delusions, or thought disorders, current suicidal or
             -homicidal ideation,

          -  expressed interest in methadone treatment,

          -  were required to use opioids for medical purposes,

          -  earned over $200 in taxable income over the previous 30 days,

          -  had physical limitations that would prevent them from using a keyboard, or were
             incarcerated or under constant monitoring by the criminal justice system.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Silverman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Johns Hopkins University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Center for Learning and Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>DeFulio A, Everly JJ, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend. 2012 Jan 1;120(1-3):48-54. doi: 10.1016/j.drugalcdep.2011.06.023. Epub 2011 Jul 22.</citation>
    <PMID>21782353</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <results_first_submitted>August 30, 2016</results_first_submitted>
  <results_first_submitted_qc>November 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 26, 2017</results_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Work Plus Naltrexone Prescription</title>
          <description>Participants who completed the oral naltrexone induction (N=38) were randomly assigned to one of two groups. Both groups were invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Prescription&quot; condition could work and earn salary independent of whether or not they took depot naltrexone injections.</description>
        </group>
        <group group_id="P2">
          <title>Work Plus Naltrexone Contingency</title>
          <description>Participants who completed the oral naltrexone induction (N=38) were randomly assigned to one of two groups. Both groups were invited to work in the Therapeutic Workplace and were prescribed depot naltrexone for 6 months. &quot;Work Plus Naltrexone Contingency&quot; participants were required to take monthly depot naltrexone injections to work and earn salary.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Work Plus Naltrexone Prescription</title>
          <description>Work Plus Naltrexone Prescription
employment-based reinforcement: Vivitrol, an extended-release depot formulation of naltrexone, will be used. Participants will be offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition will earn access to working and earning salary by taking depot naltrexone injections once per month. &quot;Work Plus Naltrexone Prescription&quot; participants will be encouraged to take depot naltrexone monthly, but access to working and earning salary will not be contingent on doing so.</description>
        </group>
        <group group_id="B2">
          <title>2 Work Plus Naltrexone Contingency</title>
          <description>Work Plus Naltrexone Contingency
employment-based reinforcement: Vivitrol, an extended-release depot formulation of naltrexone, will be used. Participants will be offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition will earn access to working and earning salary by taking depot naltrexone injections once per month. &quot;Work Plus Naltrexone Prescription&quot; participants will be encouraged to take depot naltrexone monthly, but access to working and earning salary will not be contingent on doing so.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="10"/>
                    <measurement group_id="B2" value="45" spread="8"/>
                    <measurement group_id="B3" value="44" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Naltrexone Injections Received</title>
        <description>The percentage of depot naltrexone doses that participants received</description>
        <time_frame>24 weeks</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Work Plus Naltrexone Prescription</title>
            <description>Participants who completed the oral naltrexone induction (N=38) were randomly assigned to one of two groups. Both groups were invited to work in the Therapeutic Workplace and were prescribed depot naltrexone injections for 6 months. Participants in the &quot;Work Plus Naltrexone Prescription&quot; condition could work and earn wages independent of whether or not the took scheduled injections.</description>
          </group>
          <group group_id="O2">
            <title>Work Plus Naltrexone Contingency</title>
            <description>Participants who completed the oral naltrexone induction (N=38) were randomly assigned to one of two groups. Both groups were invited to work in the Therapeutic Workplace and were prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition earned access to working and earning salary by taking depot naltrexone injections once per month.</description>
          </group>
        </group_list>
        <measure>
          <title>Naltrexone Injections Received</title>
          <description>The percentage of depot naltrexone doses that participants received</description>
          <population>intent-to-treat</population>
          <units>Percentage of injections received</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="86.8" lower_limit="33" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.002</p_value>
            <method>General Estimating Equation (GEE)</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.44</ci_lower_limit>
            <ci_upper_limit>25.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to the First Missed Dose</title>
        <description>The time to the first missed dose of depot naltrexone</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Work Plus Naltrexone Prescription</title>
            <description>Participants could work and earn vouchers but did not to take naltrexone to work and earn vouchers.</description>
          </group>
          <group group_id="O2">
            <title>Work Plus Naltrexone Contingency</title>
            <description>Participants could work and earn vouchers and had to take naltrexone to work and earn vouchers: employment-based reinforcement.
employment-based reinforcement: Vivitrol, an extended-release depot formulation of naltrexone, will be used. Participants will be offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition will earn access to working and earning salary by taking depot naltrexone injections once per month. &quot;Work Plus Naltrexone Prescription&quot; participants will be encouraged to take depot naltrexone monthly, but access to working and earning salary will not be contingent on doing so.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Missed Dose</title>
          <description>The time to the first missed dose of depot naltrexone</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.74" spread="7.67"/>
                    <measurement group_id="O2" value="20.84" spread="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0081</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of 30-day Urine Samples Negative for Opiates</title>
        <description>Percentage of urine samples collected at the 30-day assessments that are negative for opiates</description>
        <time_frame>Collected every 30 days for 150 days</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Work Plus Naltrexone Prescription</title>
            <description>Participants who completed the oral naltrexone induction (N=38) were randomly assigned to one of two groups. Both groups were invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone injections for 6 months. Participants in the &quot;Work Plus Naltrexone Prescription&quot; condition could work and earn wages independent of whether or not the took scheduled injections.</description>
          </group>
          <group group_id="O2">
            <title>Work Plus Naltrexone Contingency</title>
            <description>Participants who completed the oral naltrexone induction (N=38) were randomly assigned to one of two groups. Both groups were invited to work in the Therapeutic Workplace and were prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition earned access to working and earning salary by taking depot naltrexone injections once per month.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of 30-day Urine Samples Negative for Opiates</title>
          <description>Percentage of urine samples collected at the 30-day assessments that are negative for opiates</description>
          <population>intent to treat</population>
          <units>percentage of opiate negative</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="71.6" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>General Estimating Equation (GEE)</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.5</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of M-W-F Samples Negative for Cocaine</title>
        <description>Percentage of urine samples collected Monday, Wednesday and Friday at the workplace that are negative for cocaine</description>
        <time_frame>Collected every Monday, Wednesday and Friday for 24 weeks</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Work Plus Naltrexone Prescription</title>
            <description>Participants who completed the oral naltrexone induction (N=38) were randomly assigned to one of two groups. Both groups were invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. &quot;Work Plus Naltrexone Prescription&quot; participants were encouraged to take depot naltrexone monthly, but access to working and earning salary was not contingent on doing so.</description>
          </group>
          <group group_id="O2">
            <title>Work Plus Naltrexone Contingency</title>
            <description>Participants who completed the oral naltrexone induction (N=38) were randomly assigned to one of two groups. Both groups were invited to work in the Therapeutic Workplace and were prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition earned access to working and earning salary by taking depot naltrexone injections once per month.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of M-W-F Samples Negative for Cocaine</title>
          <description>Percentage of urine samples collected Monday, Wednesday and Friday at the workplace that are negative for cocaine</description>
          <population>intent to treat</population>
          <units>percentage of mwf cocaine negative</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" lower_limit="0" upper_limit="97"/>
                    <measurement group_id="O2" value="54.6" lower_limit="1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.41</p_value>
            <method>General Estimating Equation (GEE)</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.6</ci_lower_limit>
            <ci_upper_limit>3.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Percentage of 30-day Urine Samples Negative for Cocaine</title>
        <description>The percentage of urine samples collected at 30-day assessments that are negative for cocaine.</description>
        <time_frame>Collected every 30 days for 150 days</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Work Plus Naltrexone Prescription</title>
            <description>Participants could work and earn vouchers but did not to take Vivitrol Injections to work and earn vouchers.</description>
          </group>
          <group group_id="O2">
            <title>Work Plus Naltrexone Contingency</title>
            <description>Participants could work and earn vouchers and had to take Vivitrol Injections to work and earn vouchers: employment-based reinforcement.
Work Plus Naltrexone Contingency: Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition earned access to working and earning salary by taking depot naltrexone injections once per month.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Percentage of 30-day Urine Samples Negative for Cocaine</title>
          <description>The percentage of urine samples collected at 30-day assessments that are negative for cocaine.</description>
          <population>intent to treat</population>
          <units>percentage cocaine negative urine sample</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="57.9" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>General Estimating Equation (GEE)</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.42</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Risk Behaviors</title>
        <description>behaviors that place participants at risk for acquiring or transmitting HIV infection</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Work Plus Naltrexone Prescription</title>
            <description>Participants who complete the oral naltrexone induction (N=38)were randomly assigned to one of two groups. Both groups were invited to work in the Therapeutic Workplace and were prescribed depot naltrexone for 6 months.&quot;Work Plus Naltrexone Prescription&quot; participants were encouraged to take depot naltrexone monthly, but access to working and earning salary was not contingent on doing so.</description>
          </group>
          <group group_id="O2">
            <title>Work Plus Naltrexone Contingency</title>
            <description>Participants who complete the oral naltrexone induction (N=38) were randomly assigned to one of two groups. Both groups were invited to work in the Therapeutic Workplace and were prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition earned access to working and earning salary by taking depot naltrexone injections once per month.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Risk Behaviors</title>
          <description>behaviors that place participants at risk for acquiring or transmitting HIV infection</description>
          <units>percentage of months reported</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="14.4"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1543</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of M,W,F Urine Samples Negative for Opiates</title>
        <description>Percentage of urine samples collected Monday, Wednesday and Friday at the workplace that are negative for opiates</description>
        <time_frame>Collected every Monday, Wednesday and Friday for 24 weeks</time_frame>
        <population>intent to treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Work Plus Naltrexone Prescription</title>
            <description>Participants could work and earn vouchers but did not to take naltrexone to work and earn vouchers.</description>
          </group>
          <group group_id="O2">
            <title>Work Plus Naltrexone Contingency</title>
            <description>Participants could work and earn vouchers and had to take naltrexone to work and earn vouchers: employment-based reinforcement.
employment-based reinforcement: Vivitrol, an extended-release depot formulation of naltrexone, will be used. Participants will be offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition will earn access to working and earning salary by taking depot naltrexone injections once per month. &quot;Work Plus Naltrexone Prescription&quot; participants will be encouraged to take depot naltrexone monthly, but access to working and earning salary will not be contingent on doing so.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of M,W,F Urine Samples Negative for Opiates</title>
          <description>Percentage of urine samples collected Monday, Wednesday and Friday at the workplace that are negative for opiates</description>
          <population>intent to treatment</population>
          <units>percentage of opiate negative</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="4" upper_limit="99"/>
                    <measurement group_id="O2" value="66.2" lower_limit="7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>General Estimating Equation (GEE)</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.81</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Every month for 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 Work Plus Naltrexone Prescription</title>
          <description>Work Plus Naltrexone Prescription
employment-based reinforcement: Vivitrol, an extended-release depot formulation of naltrexone, will be used. Participants will be offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition will earn access to working and earning salary by taking depot naltrexone injections once per month. &quot;Work Plus Naltrexone Prescription&quot; participants will be encouraged to take depot naltrexone monthly, but access to working and earning salary will not be contingent on doing so.</description>
        </group>
        <group group_id="E2">
          <title>2 Work Plus Naltrexone Contingency</title>
          <description>Work Plus Naltrexone Contingency
employment-based reinforcement: Vivitrol, an extended-release depot formulation of naltrexone, will be used. Participants will be offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the &quot;Work Plus Naltrexone Contingency&quot; condition will earn access to working and earning salary by taking depot naltrexone injections once per month. &quot;Work Plus Naltrexone Prescription&quot; participants will be encouraged to take depot naltrexone monthly, but access to working and earning salary will not be contingent on doing so.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sleeplessness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reduced sex drive</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kenneth Silverman</name_or_title>
      <organization>Johns Hopkins School of Medicine: Department of Psychiatry‚Äù</organization>
      <phone>410-550-2694</phone>
      <email>ksilverm@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

